Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sultiame
- Development stage
- Phase 2
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sultiame is an antiepileptic drug primarily used to treat benign focal epilepsies of childhood. It acts as a carbonic anhydrase inhibitor, which helps stabilize neurons and reduce seizures. It is also being explored for its potential in treating obstructive sleep apnea (OSA).
- Brand names
- Ospolot
- Other names
- sulthiamesultiamosultiamum
02
Targets
CA6 (Carbonic Anhydrase 6)CA4 (Carbonic anhydrase 4)CA5A (Carbonic anhydrase VA)CA7 (Carbonic anhydrase VII)CA2 (Carbonic Anhydrase 2)CA12 (Carbonic anhydrase XII)CA9 (Carbonic anhydrase IX)
Beyond the preview
Go deeper on sultiame.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sultiame.